PMID- 35536197
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220808
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 52
IP  - 8
DP  - 2022 Aug
TI  - Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib 
      for intermediate-stage hepatocellular carcinoma.
PG  - 721-729
LID - 10.1111/hepr.13773 [doi]
AB  - AIM: Transarterial chemoembolization (TACE) combined with a PD-1 inhibitor and 
      TACE combined with a PD-1 inhibitor and lenvatinib have recently been reported as 
      promising treatments to improve the prognosis of hepatocellular carcinoma (HCC) 
      patients. This study aims to compare the efficacy of these two treatments. 
      METHODS: A retrospective study was conducted, and patients were recruited from 
      two centers in China. Progression-free survival (PFS) and overall survival (OS) 
      were compared, and the objective response rate (ORR) and disease control rate 
      (DCR) were evaluated according to the modified Response Evaluation Criteria in 
      Solid Tumors (mRECIST). Treatment-related adverse events (AEs) were analyzed to 
      assess safety. RESULTS: The median follow-up for the entire cohort was 
      11.4 months. Of the 103 patients included in this study, 56 received triple 
      therapy, and 47 received doublet therapy. PFS was significantly higher in the 
      triple therapy group than in the doublet therapy group (mPFS 22.5 vs. 
      14.0 months, P < 0.001). Similar results were obtained in terms of OS 
      (P = 0.001). The ORR and DCR were also better in the triple therapy group (64.3% 
      vs. 38.3%, P = 0.010; 85.7% vs. 57.4%, P = 0.002). The most common AEs in the 
      triple therapy group were decreased albumin (55.3%), decreased platelet count 
      (51.8%) and hypertension (44.6%). CONCLUSIONS: The combination of TACE with a 
      PD-1 inhibitor and lenvatinib in patients with BCLC stage B HCC might result in 
      significantly improved clinical outcomes with a manageable safety profile 
      compared with TACE with a PD-1 inhibitor.
CI  - (c) 2022 Japan Society of Hepatology.
FAU - Xiang, Yan-Jun
AU  - Xiang YJ
AUID- ORCID: 0000-0002-7378-6724
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou 
      Medical University, Wenzhou, China.
FAU - Wang, Kang
AU  - Wang K
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
FAU - Yu, Hong-Ming
AU  - Yu HM
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
FAU - Li, Xiao-Wei
AU  - Li XW
AD  - Department II of Interventional Radiology, Eastern Hepatobiliary Surgery 
      Hospital, Naval Medical University, Shanghai, China.
FAU - Cheng, Yu-Qiang
AU  - Cheng YQ
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
FAU - Wang, Wei-Jun
AU  - Wang WJ
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
FAU - Feng, Jin-Kai
AU  - Feng JK
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
FAU - Bo, Meng-Han
AU  - Bo MH
AD  - Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
FAU - Qin, Ying-Yi
AU  - Qin YY
AD  - Department of Health Statistics, Naval Medical University, Shanghai, China.
FAU - Zheng, Yi-Tao
AU  - Zheng YT
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou 
      Medical University, Wenzhou, China.
FAU - Shan, Yun-Feng
AU  - Shan YF
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou 
      Medical University, Wenzhou, China.
FAU - Zhou, Li-Ping
AU  - Zhou LP
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
FAU - Zhai, Jian
AU  - Zhai J
AD  - Department II of Interventional Radiology, Eastern Hepatobiliary Surgery 
      Hospital, Naval Medical University, Shanghai, China.
FAU - Cheng, Shu-Qun
AU  - Cheng SQ
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval 
      Medical University, Shanghai, China.
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou 
      Medical University, Wenzhou, China.
LA  - eng
GR  - 81730097/State Key Program of National Natural Science Foundation of China/
GR  - SHDC2020CR1004A/Clinical Research Plan of Shanghai Hospital Development Center/
GR  - 19411967300/Science and Technology Commission Foundation of Shanghai 
      Municipality/
GR  - 82072618/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20220522
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - lenvatinib
OT  - sintilimab
OT  - toripalimab
OT  - transarterial chemoembolization
EDAT- 2022/05/11 06:00
MHDA- 2022/05/11 06:01
CRDT- 2022/05/10 10:43
PHST- 2022/04/12 00:00 [revised]
PHST- 2022/03/24 00:00 [received]
PHST- 2022/04/26 00:00 [accepted]
PHST- 2022/05/11 06:00 [pubmed]
PHST- 2022/05/11 06:01 [medline]
PHST- 2022/05/10 10:43 [entrez]
AID - 10.1111/hepr.13773 [doi]
PST - ppublish
SO  - Hepatol Res. 2022 Aug;52(8):721-729. doi: 10.1111/hepr.13773. Epub 2022 May 22.